From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women
Issued Date
2024-05-01
Resource Type
eISSN
15720241
Scopus ID
2-s2.0-85181906349
Pubmed ID
38147513
Journal Title
The American journal of gastroenterology
Volume
119
Issue
5
Start Page
893
End Page
909
Rights Holder(s)
SCOPUS
Bibliographic Citation
The American journal of gastroenterology Vol.119 No.5 (2024) , 893-909
Suggested Citation
Danpanichkul P., Ng C.H., Muthiah M., Suparan K., Tan D.J.H., Duangsonk K., Sukphutanan B., Kongarin S., Harinwan N., Panpradist N., Takahashi H., Kawaguchi T., Vichitkunakorn P., Chaiyakunapruk N., Nathisuwan S., Huang D., Arab J.P., Noureddin M., Mellinger J.L., Wijarnpreecha K. From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women. The American journal of gastroenterology Vol.119 No.5 (2024) , 893-909. 909. doi:10.14309/ajg.0000000000002642 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98320
Title
From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women
Author's Affiliation
School of Medicine, Mae Fah Luang University
Faculty of Medicine
National University Health System
Escuela de Medicina
University of Michigan Medical School
Faculty of Medicine, Chiang Mai University
Schulich School of Medicine & Dentistry
University of California, San Diego
London Health Sciences Centre
NUS Yong Loo Lin School of Medicine
Faculty of Medicine, Prince of Songkla University
University of Washington
Mahidol University
University of Utah Health
Houston Methodist
University of Arizona College of Medicine – Phoenix
Banner - University Medical Center Phoenix
Kurume University School of Medicine
Faculty of Medicine
National University Health System
Escuela de Medicina
University of Michigan Medical School
Faculty of Medicine, Chiang Mai University
Schulich School of Medicine & Dentistry
University of California, San Diego
London Health Sciences Centre
NUS Yong Loo Lin School of Medicine
Faculty of Medicine, Prince of Songkla University
University of Washington
Mahidol University
University of Utah Health
Houston Methodist
University of Arizona College of Medicine – Phoenix
Banner - University Medical Center Phoenix
Kurume University School of Medicine
Corresponding Author(s)
Other Contributor(s)
Abstract
INTRODUCTION: The burden of alcohol-related complications is considerable, particularly alcohol-associated liver disease and alcohol use disorder (AUD). However, there are deficiencies in comprehensive epidemiological research focusing on these issues, especially among young women who display higher susceptibility to such complications compared with their male counterparts. We thus aimed to determine the global burden of these conditions in this vulnerable group. METHODS: Leveraging data from the Global Burden of Disease Study 2019, we analyzed the prevalence, mortality, and disability-adjusted life years of alcohol-associated cirrhosis (AC), liver cancer from alcohol, and AUD in young women. The findings were categorized by region, nation, and sociodemographic index. RESULTS: The highest age-standardized prevalence rates were observed in AUD (895.96 [95% uncertainty interval (UI) 722.6-1,103.58]), followed by AC (65.33 [95% UI 48.37-86.49]) and liver cancer from alcohol (0.13 [95% UI 0.09-0.19]) per 100,000 people. The highest age-standardized mortality rates were observed in AC (0.75 [95% UI 0.55-0.97]), followed by AUD (0.48 [95% UI 0.43-0.53]) and liver cancer from alcohol (0.06 [95% UI 0.04-0.09]). The highest burdens of AC and AUD were observed in Central Europe, whereas the high-income Asia Pacific had the highest burden of liver cancer from alcohol. DISCUSSION: Throughout the past decade, the trend of AUD varied among regions while the impact of alcohol-associated liver disease has increased, requiring urgent public health strategy to mitigate these complications, particularly in female patients in Europe and the Asia-Pacific region.